JP5155309B2 - 患者の循環液中のMMP−7の測定を利用した転移した膀胱ガンを診断およびモニターするためのinvitro方法 - Google Patents
患者の循環液中のMMP−7の測定を利用した転移した膀胱ガンを診断およびモニターするためのinvitro方法 Download PDFInfo
- Publication number
- JP5155309B2 JP5155309B2 JP2009514694A JP2009514694A JP5155309B2 JP 5155309 B2 JP5155309 B2 JP 5155309B2 JP 2009514694 A JP2009514694 A JP 2009514694A JP 2009514694 A JP2009514694 A JP 2009514694A JP 5155309 B2 JP5155309 B2 JP 5155309B2
- Authority
- JP
- Japan
- Prior art keywords
- mmp
- bladder cancer
- metastatic bladder
- cancer
- circulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims description 93
- 201000005112 urinary bladder cancer Diseases 0.000 title claims description 92
- 206010005003 Bladder cancer Diseases 0.000 title claims description 91
- 108090000855 Matrilysin Proteins 0.000 title claims description 52
- 206010061289 metastatic neoplasm Diseases 0.000 title claims description 38
- 230000001394 metastastic effect Effects 0.000 title claims description 37
- 238000000034 method Methods 0.000 title claims description 28
- 238000005259 measurement Methods 0.000 title claims description 24
- 238000000338 in vitro Methods 0.000 title claims description 8
- 238000012544 monitoring process Methods 0.000 title claims description 8
- 239000012530 fluid Substances 0.000 title claims description 5
- 102100030417 Matrilysin Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 102000004318 Matrilysin Human genes 0.000 claims description 49
- 201000011510 cancer Diseases 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 21
- 239000000090 biomarker Substances 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 230000002596 correlated effect Effects 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 5
- 239000000439 tumor marker Substances 0.000 claims description 4
- 238000007619 statistical method Methods 0.000 claims description 3
- 108010036226 antigen CYFRA21.1 Proteins 0.000 claims description 2
- 238000004590 computer program Methods 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 2
- 102000010911 Enzyme Precursors Human genes 0.000 claims 1
- 108010062466 Enzyme Precursors Proteins 0.000 claims 1
- 101100130647 Rattus norvegicus Mmp7 gene Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 30
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 22
- 206010027476 Metastases Diseases 0.000 description 20
- 102000005741 Metalloproteases Human genes 0.000 description 17
- 108010006035 Metalloproteases Proteins 0.000 description 17
- 230000009401 metastasis Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 206010044412 transitional cell carcinoma Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- 239000013060 biological fluid Substances 0.000 description 5
- 238000002574 cystoscopy Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 102000052074 human MMP7 Human genes 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 240000006570 Euonymus japonicus Species 0.000 description 2
- 235000016796 Euonymus japonicus Nutrition 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 2
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000000282 fibrinogen degradation product Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003741 urothelium Anatomy 0.000 description 2
- 108091071337 20 family Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
一般名「膀胱ガン(bladder cancer)」は、3つの一般的な疾患グループ(表在性、浸潤性および転移性)に分けることができる様々な疾患を表す膀胱ガン(urinary bladder cancer)のために使用される。「膀胱ガン」は、発生率と死亡率の両方で、男性で四番目に多いガンであり、女性では八番目に多いガンである(Cohen SC et al., Urol. Clin. N. Am (1992) 19, 421-428; Boring CC et al., CA Cancer J. Clin (1994) 44, 7-26)。膀胱ガンの症例の90%以上が、移行上皮ガン(TCC)であり、約5%が、扁平上皮ガン(SCC)であり、2%未満が腺ガンである。
その発現が様々な型の膀胱ガンにおいて変化することが見出されている生体分子としては、マトリックスメタロプロテアーゼ(MMP)および前記メタロプロテアーゼの活性に影響を及ぼす組織性インヒビター(tissue inhibitor of matrix metalloproteinase: TIMP)がある(SUMI T et al.: “Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder”, Oncol Rep. 2003, Mar-Apr; 10(2); 345-349; FURUKAWA A at al.: “Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency”, Urology 1998, May; 51(5): 849-853を参照)。
少なくとも1つの更に確立された腫瘍マーカーの測定と組み合わせた共マーカー(co-marker)としての、膀胱ガンであることが疑われる患者の循環液中における、MMP-7、MMP-7の前駆体および/またはMMP-7免疫応答性を有するMMP-7の断片の測定を包含する。例示のみとして、前記少なくとも1つの更に確立された腫瘍マーカーは、CEA、AFP、TPA、CYFRA 21-1、CA 19-9、CA 125、CA 72-4(TAG-72)、CA 15-3、CA 549、hCG、MCA、NSE、PSA、SCC、LDH(乳酸脱水素酵素)およびPAL(アルカリホスファターゼ)からなる群から選択することができる。
[血清サンプル]
全ての血清サンプルを、原発性膀胱ガンであると診断された患者(n=38)、転移性膀胱ガンであると診断された患者(n=60)、または(各個人にインフォームドコンセントを行った後の)正常なボランティアドナー(n=111)のいずれから取り出した様々なヒトの血液サンプルから単離した。
Human MMP-7 Quantikine ELISA Kit(DMP700)(R&D Systems Europe Ltd. Abingdon UK)を使用して、R&D Systemsのプロトコールに従って、アッセイを実施した。
[a)標準曲線および膀胱ガン(BC)の患者の血清中のMMP-7レベルの測定]
標準曲線は、組み換えヒトMMP-7(Quantikine kit standards)を使用して得た。組み換えヒトMMP-7は、キャリブレーター希釈液RD6-28(Quantikine kit)中で希釈し、0.156、0.312、0.625、1.25、2.5、5および10ng/mlのMMP-7標準濃度を得た。
臨床的感度 対 臨床的特異性の図表を、ROC(Receiver-Operating Characteristics)曲線によって表わす。
Claims (10)
- ヒト患者における転移性膀胱ガンの検出、早期検出、モニターおよび/または予後のためのバイオマーカーとしての、循環マトリックスメタロプロテアーゼ7(MMP-7)、循環MMP-7の前駆体(プロ-MMP-7)、および/またはMMP-7免疫応答性を有する循環MMP-7の断片の使用であって、前記のMMP-7、プロ-MMP-7、および/またはMMP-7免疫応答性を有するMMP-7断片のレベルの増加が、転移性膀胱ガンの悪性挙動と正に相関している、使用。
- ヒト患者の循環液に由来するサンプルにおいて、そのレベルが転移性膀胱ガンの存在および/または重篤度の指標であるバイオマーカーを測定すること、ならびに、測定したバイオマーカーのレベルを、転移性膀胱ガンの存在または重篤度と関連付けることによる、前記患者における転移性膀胱ガンを診断またはモニターするための、in vitro方法であって、前記測定されるバイオマーカーが、測定可能なMMP-7免疫応答性として直接的に測定されるMMP-7であり、前記MMP-7のレベルの増加が、転移性膀胱ガンの悪性挙動と正に相関している、方法。
- 膀胱ガンの患者から得られた血清または血漿サンプルにおいて、選択した連続的な時間間隔でMMP-7免疫応答性のレベルを測定することを含む、前記患者における、転移性膀胱ガンの進行をモニターするための方法であって、経時的なMMP-7の測定レベルの変化が、転移性膀胱ガンの進行の指標である方法として実施される、請求項2に記載の方法。
- 前記患者から得られた血清または血漿サンプルにおいて、選択した連続的な時間間隔でMMP-7免疫応答性のレベルを測定することを含む、転移性膀胱ガンの治療の効果を測定するための方法であって、測定間のMMP-7の測定レベルの減少が、治療の効果を示す方法として実施される、請求項2に記載の方法。
- MMP-7免疫応答性を、特定のリガンドアッセイ手法を用いて選択的に測定する、請求項2から4のいずれか一項に記載の方法。
- MMP-7免疫応答性を、MMP-7に特異的に結合する少なくとも1つの特異的なリガンドを使用するアッセイを用いて測定する、請求項5に記載の方法。
- 測定されるMMP-7免疫応答性が、MMP-7それ自身および/またはその酵素前駆体形態(プロ-MMP-7)および/またはMMP-7免疫応答性を有するMMP-7断片の存在に起因しうる、請求項2から6のいずれか一項に記載の方法。
- 転移性膀胱ガンの診断に潜在的に相関している1を超えるバイオマーカーの測定の統計学的分析のためのコンピュータープログラムを使用して、MMP-7およびMMP-7免疫応答性のそれぞれの測定結果が、診断目的用に、少なくとも1つの更なる確立された腫瘍マーカーの測定結果と組み合わせられる、請求項2から7のいずれか一項に記載の方法。
- 少なくとも1つの更なる確立された腫瘍マーカーが、CEA、AFP、TPA、CYFRA 21-1、CA 19-9、CA 125、CA 72-4(TAG-72)、CA 15-3、CA 549、hCG、MCA、NSE、PSA、SCC、LDH、PALからなる群から選択される、請求項8に記載の方法。
- ヒト患者における転移性膀胱ガンの検出、早期検出、モニターおよび/または予後のための、循環マトリックスメタロプロテアーゼ7(MMP-7)、循環MMP-7の前駆体(プロ-MMP-7)および/またはMMP-7免疫応答性を有する循環MMP-7の断片の、確立された腫瘍マーカーと組み合わせての共バイオマーカーとしての使用であって、前記のMMP-7、プロ-MMP-7、および/またはMMP-7免疫応答性を有するMMP-7断片のレベルの増加が、転移性膀胱ガンの悪性挙動と正に相関している、使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290988A EP1867995A1 (en) | 2006-06-15 | 2006-06-15 | In vitro method for diagnosing and monitoring metastasized bladder cancer using the determination of MMP-7 in the circulation of patients |
EP06290988.2 | 2006-06-15 | ||
PCT/EP2007/005178 WO2007144144A1 (en) | 2006-06-15 | 2007-06-12 | In vitro method for diagnosing and monitoring metastasized bladder cancer using the determination of mmp -7 in the circulation of patients |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009540308A JP2009540308A (ja) | 2009-11-19 |
JP5155309B2 true JP5155309B2 (ja) | 2013-03-06 |
Family
ID=36997848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009514694A Active JP5155309B2 (ja) | 2006-06-15 | 2007-06-12 | 患者の循環液中のMMP−7の測定を利用した転移した膀胱ガンを診断およびモニターするためのinvitro方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100028909A1 (ja) |
EP (2) | EP1867995A1 (ja) |
JP (1) | JP5155309B2 (ja) |
WO (1) | WO2007144144A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
ES2567079T3 (es) | 2007-11-02 | 2016-04-19 | Momenta Pharmaceuticals, Inc. | Composiciones de polisacáridos que no son anticoagulantes |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
WO2010121196A1 (en) * | 2009-04-16 | 2010-10-21 | Momenta Pharmaceuticals, Inc. | Methods of assessing activity of a polysaccharide composition |
US9387256B2 (en) | 2010-04-16 | 2016-07-12 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
WO2014193818A1 (en) | 2013-05-28 | 2014-12-04 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
US20190086419A1 (en) | 2016-03-09 | 2019-03-21 | Cézanne S.A.S. | Chromogranin a as a marker for bladder cancer |
US10366999B2 (en) * | 2016-03-31 | 2019-07-30 | Xilinx, Inc. | Single event upset (SEU) mitigation for FinFET technology using fin topology |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2949467B2 (ja) * | 1995-02-16 | 1999-09-13 | 富士薬品工業株式会社 | 免疫学的測定法によるヒトプロマトリックスメタロプロテアーゼ7の定量 |
US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
US20040076955A1 (en) * | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
JP2003321494A (ja) * | 2002-02-26 | 2003-11-11 | Daiichi Fine Chemical Co Ltd | プロmmp−7の活性化調節方法 |
EP1706720A4 (en) * | 2003-10-31 | 2007-02-28 | Vitatex Inc | BLOOD TEST PROTOTYPES AND METHOD FOR DETECTING CIRCULATING TUMOR AND ENDOTHELIAL CELLS |
-
2006
- 2006-06-15 EP EP06290988A patent/EP1867995A1/en not_active Withdrawn
-
2007
- 2007-06-12 JP JP2009514694A patent/JP5155309B2/ja active Active
- 2007-06-12 EP EP07725984.4A patent/EP2035834B1/en active Active
- 2007-06-12 WO PCT/EP2007/005178 patent/WO2007144144A1/en active Application Filing
- 2007-06-12 US US12/304,643 patent/US20100028909A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2007144144A1 (en) | 2007-12-21 |
EP2035834B1 (en) | 2017-11-15 |
US20100028909A1 (en) | 2010-02-04 |
EP1867995A1 (en) | 2007-12-19 |
JP2009540308A (ja) | 2009-11-19 |
EP2035834A1 (en) | 2009-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5155309B2 (ja) | 患者の循環液中のMMP−7の測定を利用した転移した膀胱ガンを診断およびモニターするためのinvitro方法 | |
JP5355086B2 (ja) | 腎細胞癌(RCC)に対する体液性バイオマーカーとしてMMP−7を使用する、RCCを診断及びモニターするためのinvitro方法 | |
JP5563988B2 (ja) | 癌のマーカーとしてのセプラーゼ | |
JP4183757B2 (ja) | 子宮内膜ガンの検出 | |
JP4847873B2 (ja) | 上皮起源の癌を診断および予後診断するための方法 | |
JP4638608B2 (ja) | 癌マーカーとしての1型マトリクスメタロプロテイナーゼ組織阻害剤(timp−1) | |
US20210270836A1 (en) | Method for the in vitro diagnosis of prostate cancer by means of urinary biomarkers | |
EP3427058B1 (en) | Chromogranin a as a marker for bladder cancer | |
US20070269831A1 (en) | Method for Early Detection of Ovarian Cancer | |
CN105510586B (zh) | 用于肺癌诊断的试剂盒及其使用方法 | |
Swellam et al. | Clinical implications of proteolytic activity imbalance in breast cancer diagnosis | |
Zitella et al. | Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia | |
AU6385998A (en) | Detection of endometrial cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100604 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110920 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120319 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121206 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5155309 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |